Biocept Inc. (NASDAQ: BIOC) stock gained by 3.13% in the current market trading. Biocept creates and sells molecular diagnostic tests that offer doctors with clinically useful information for treating and monitoring patients with a range of malignancies.
What is happening?
Quest Diagnostics has partnered with BIOC to layout laboratory testing facilities for their Target Selector NGS-based liquid biopsy targeted lung cancer panel to Quest patients. Quest Diagnostics is the world’s largest provider of diagnostic information services, which includes sophisticated diagnostics.
The Biocept Target Selector NGS-based liquid biopsy assay is a somewhat invasive, lab-developed testing that may be used for genomic profiling in advanced non-small cell lung cancer (NSCLC) individuals to assist qualify them for advanced targeted treatments and track treatment efficacy. Patients will be able to give a blood sample for testing at one of Quest’s 2,200 conveniently placed patient care locations across the United States with a physician’s order. The service will be accessible to Quest Diagnostics’ clinicians and patients in the fourth quarter of 2021, according to the two parties.
Michael Nall, President, and CEO of Biocept stated,
BIOC is thrilled to expand Biocept’s partnership with Quest Diagnostics, as they believe its competence and reach will enable them to serve more patients and ultimately expand their client base. Quest shares their commitment to improve lung cancer care, and this partnership will enable them to give oncologists with the information they need to build more tailored, responsive treatment regimens for their patients.
Kristie Dolan, General Manager, Oncology Franchise, Quest Diagnostics commented,
Lung cancer is one of the most common and lethal types of cancer. To enhance patient outcomes, better tools to help in therapy selection and monitoring are urgently required, which is why they are so thrilled to collaborate with Biocept on this targeted test. Quest offers the national size, oncology knowledge, and network provider relationships needed to expand access to this significant breakthrough, which might enhance care for lung cancer patients.